J.C. Yang

O005 : Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks

Eric Lawitz, Steven L. Flamm, J.C. Yang et al. · Journal of Hepatology · 2015 · 131 citations

Treatment And Prevention, Ledipasvir/sofosbuvir-based Regimens, Patient Safety +5

GS‐9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double‐blind, dose‐ranging phase 1 study

M. Rodríguez‐Torres, S. Glass, John M. Hill et al. · Journal of Viral Hepatitis · 2016 · 65 citations · Full text

Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong

Ching‐Lung Lai, Vincent Wai‐Sun Wong, Man‐Fung Yuen et al. · Alimentary Pharmacology & Therapeutics · 2015 · 29 citations · Full text

Community‐based real‐world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States

Robert J. Wong, Mai Thanh Thi Nguyen, Huy N. Trinh et al. · Journal of Viral Hepatitis · 2016 · 15 citations · Full text

Hepatitis B, Antiviral Drug, United States +21

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals

Eric Lawitz, Kris V. Kowdley, Michael P. Curry et al. · Journal of Hepatology · 2016 · 13 citations

Viral Hepatitis, Direct-acting Antivirals, Antiviral Drug Development +9